

NYMOX PHARMACEUTICAL CORP

Form 6-K

November 06, 2017

## **FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**under the Securities Exchange Act of 1934**

For the period ended **September 30, 2017**

Commission File Number: **001-12033**

### **Nymox Pharmaceutical Corporation**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing

the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

**Exhibits**

- 99.1     Quarterly Report for the Quarter ended September 30, 2017
- 99.2     CEO Certifications
- 99.3     CFO Certifications

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL  
CORPORATION  
(Registrant)

Date: November 6, 2017

By: */s/ Paul Averbach, MD*  
Paul Averbach, MD  
President and Chief Executive Officer